{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/prostate-cancer/prescribing-information/cyproterone-acetate/","result":{"pageContext":{"chapter":{"id":"80712d44-9544-56aa-aa10-d4cd640429de","slug":"cyproterone-acetate","fullItemName":"Cyproterone acetate","depth":2,"htmlHeader":"<!-- begin field e852a05f-f941-40ba-bf4b-b28531631054 --><h2>Cyproterone acetate</h2><!-- end field e852a05f-f941-40ba-bf4b-b28531631054 -->","summary":"","htmlStringContent":"<!-- begin item 7667dbef-0f1f-40e4-8503-bd82ccb8fafa --><!-- end item 7667dbef-0f1f-40e4-8503-bd82ccb8fafa -->","topic":{"id":"2ab521f2-aa56-5e1e-b28e-fc4d637a303c","topicId":"1506c25e-8998-42e4-82c0-6b38dc3a1e9f","topicName":"Prostate cancer","slug":"prostate-cancer","lastRevised":"Last revised in October 2017","chapters":[{"id":"324faedd-14d8-5d99-8059-d9428da432ea","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"276607b5-8522-5d5e-86f1-d9be97d83a94","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"df8fe922-4f04-5594-b4a9-fc0935cf3b16","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"d95f0cd5-43fd-5950-b45a-5d312e16b3e3","slug":"changes","fullItemName":"Changes"},{"id":"dc0f462f-4d9f-503f-ae6e-64aa386af1e8","slug":"update","fullItemName":"Update"}]},{"id":"fb4bea73-b877-5f11-9f5e-f4b1a776c6ab","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"d9df68e4-4518-5224-b388-b610695e181f","slug":"goals","fullItemName":"Goals"},{"id":"cbda6200-7ae0-5f80-b984-4f2e0d78d4de","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"b6c612ea-8423-5c36-abab-32784d6ed762","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"4909e587-a937-5829-873f-b3e02e5c8a36","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"b3baf3db-45b6-5fd4-94e3-cbbaf8d70bd9","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"d0703c17-2896-5c8e-a091-a6024da2508d","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"b6a5e49a-643a-5e4a-a980-dc835d73c66d","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"7fb66c84-18e5-52f1-b7ef-daf96c4f903c","slug":"definition","fullItemName":"Definition"},{"id":"ae301838-d2bd-55ed-a057-844f73f6942a","slug":"causes","fullItemName":"Causes"},{"id":"5656e958-479a-5103-96a1-2b0d6c62c156","slug":"prevalence","fullItemName":"Prevalence"},{"id":"49f9ec22-1376-50e7-8891-e6050fbb5069","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"cf644b3b-5878-59e9-9641-63847a7f0cb5","slug":"prognosis","fullItemName":"Prognosis"},{"id":"511452bc-068d-5f51-b489-9e89b4396cd2","slug":"complications","fullItemName":"Complications"}]},{"id":"6c4ca641-81fa-53e0-8562-431396232bd7","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"7e53b66c-2f4f-500c-a8c0-9092cbce65bf","slug":"overview","fullItemName":"Overview"},{"id":"5e184056-05a4-5462-80be-51f03c9c94a2","slug":"signs-symptoms","fullItemName":"Signs and symptoms"},{"id":"5f6622b7-59bf-51f5-b413-1f0ec1a4b8d1","slug":"psa-testing","fullItemName":"PSA testing"},{"id":"30dc380e-addd-57b7-a015-a1b250c58b3c","slug":"digital-rectal-examination","fullItemName":"Digital rectal examination"},{"id":"509e34cf-6a18-526e-a3f0-d219fa4030de","slug":"when-to-refer","fullItemName":"When to refer"},{"id":"8fdd4166-47a6-5d1b-b573-bb1ab5d09da8","slug":"confirming-diagnosis-in-secondary-care","fullItemName":"Confirming diagnosis in secondary care"}]},{"id":"9dc72b4c-cd09-5f23-b45c-6d0306fa66dc","fullItemName":"Management","slug":"management","subChapters":[{"id":"56e2a92b-f611-57ed-91c6-f6672b72750f","slug":"management","fullItemName":"Scenario: Management"},{"id":"6cf2bc9c-e41d-5e71-b490-a48c7fa4a38b","slug":"complications-adverse-effects","fullItemName":"Scenario: Complications and adverse effects"}]},{"id":"742a5289-99d4-5d61-a8c9-7fc8409f0f23","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"5009abfd-1456-55b3-844d-23b74552f90c","slug":"medroxyprogesterone-acetate","fullItemName":"Medroxyprogesterone acetate"},{"id":"80712d44-9544-56aa-aa10-d4cd640429de","slug":"cyproterone-acetate","fullItemName":"Cyproterone acetate"}]},{"id":"7bed120a-c6b8-5f7e-941d-751749f78c0e","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"1c5c0083-b591-5115-8039-cdc5113cc070","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"6562ed52-3498-5877-b63d-7bb4a7b2656a","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"e27e1bd1-e689-5a6c-a6e5-36b9fcad98a3","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"1d7864fd-9f5c-5976-a1b8-9df023b04f7e","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"e6798a57-1676-5675-b1a1-50a69534adff","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"67b2f477-e9ac-5da3-a8ab-5544ec9d70f3","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"812bede6-3d25-5e1d-ba87-ac56af0e611f","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"742a5289-99d4-5d61-a8c9-7fc8409f0f23","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"ea75bb99-67c7-577d-b35d-f656552df4a5","slug":"indications","fullItemName":"Indications","depth":3,"htmlHeader":"<!-- begin field 14021aa5-a1c1-478f-aecb-b8970ffba5ef --><h3>Indications</h3><!-- end field 14021aa5-a1c1-478f-aecb-b8970ffba5ef -->","summary":"","htmlStringContent":"<!-- begin item 8940035b-5be8-4dd8-87c7-4b69b3a7dc4a --><!-- begin field 3d963360-710d-4587-acac-890c4bd78eef --><ul><li>Cyproterone acetate is licensed for the treatment of hot flushes in men with prostate cancer who are receiving treatment with gonadorelin analogues or who have had orchidectomy.</li><li>It is also licensed:<ul><li>To suppress tumour flare with initial gonadorelin analogue therapy.</li><li>In long-term palliative treatment where gonadorelin analogues or surgery are contraindicated, not tolerated, or oral therapy is preferred.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/prostate-cancer/references/\">ABPI, 2017</a>]</p><!-- end field 3d963360-710d-4587-acac-890c4bd78eef --><!-- end item 8940035b-5be8-4dd8-87c7-4b69b3a7dc4a -->","subChapters":[]},{"id":"a3a8c6a9-910e-5244-8156-259493a3de25","slug":"dosage","fullItemName":"Dosage","depth":3,"htmlHeader":"<!-- begin field 9cab7d60-c624-4412-aff5-32432440b206 --><h3>Dose</h3><!-- end field 9cab7d60-c624-4412-aff5-32432440b206 -->","summary":"","htmlStringContent":"<!-- begin item ca50fd51-c11d-42ef-a274-bb7916cc2760 --><!-- begin field 659933fe-8431-446f-a8d6-3003d8630ec8 --><ul><li>For the treatment of hot flushes in men receiving treatment with gonadorelin analogues or who have had orchidectomy:<ul><li>Prescribe 50 mg twice daily for four weeks.</li><li>Titrate up to 50 mg three times daily if necessary.<ul><li>Doses should be taken after food. </li></ul></li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/prostate-cancer/references/\">NICE, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/prostate-cancer/references/\">ABPI, 2017</a>]</p><!-- end field 659933fe-8431-446f-a8d6-3003d8630ec8 --><!-- end item ca50fd51-c11d-42ef-a274-bb7916cc2760 -->","subChapters":[]},{"id":"511e386e-1e8b-507b-b1e8-c8da073dec52","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field a16dea55-d543-4b72-865f-7de65b3af404 --><h3>Contraindications and cautions</h3><!-- end field a16dea55-d543-4b72-865f-7de65b3af404 -->","summary":"","htmlStringContent":"<!-- begin item 59a94a72-d2d6-4d27-9730-8ea34287557a --><!-- begin field 6421d57d-9632-4c2e-b33f-7f362a223c87 --><ul><li><strong>Do not prescribe cyproterone acetate to men with</strong>:<ul><li>Liver diseases (including Dubin–Johnson syndrome or Rotor syndrome).</li><li>Meningioma or a history of meningioma.</li><li>Previous or existing liver tumours (only if these are not due to metastases from carcinoma of the prostate).</li><li>Wasting diseases (with the exception of inoperable carcinoma of the prostate).</li><li>Existing thrombosis or embolism.</li></ul></li><li><strong>Prescribe</strong> <strong>cyproterone acetate with caution to men with: </strong><ul><li>Diabetes mellitus.  </li><li>Sickle cell anaemia. </li><li>A history of arterial or venous thrombotic or thromboembolic events (for example deep vein thrombosis, pulmonary embolism, myocardial infarction).</li><li>A history of cerebrovascular disease.</li><li>Advanced cancer.</li><li>Severe depression.</li></ul></li><li>Because of the risk of hepatic toxicity, liver function tests should be performed before treatment, regularly during treatment, and whenever any symptoms or signs suggestive of hepatotoxicity occur. Stop treatment if hepatotoxicity occurs unless the hepatotoxicity is due to other causes (for example metastatic disease). </li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/prostate-cancer/references/\">BNF 73, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/prostate-cancer/references/\">ABPI, 2017</a>] </p><!-- end field 6421d57d-9632-4c2e-b33f-7f362a223c87 --><!-- end item 59a94a72-d2d6-4d27-9730-8ea34287557a -->","subChapters":[]},{"id":"c0b8c273-2c38-5b68-8d4c-9de363c568fe","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 87dc9741-354f-433c-8b04-978fa01f9220 --><h3>Adverse effects </h3><!-- end field 87dc9741-354f-433c-8b04-978fa01f9220 -->","summary":"","htmlStringContent":"<!-- begin item 23885e3c-ca44-4bcb-b38b-247eda3052ca --><!-- begin field 0c7373e3-df9d-4657-b3ae-a46ddaf170a8 --><ul><li><strong>Possible adverse effects of cyproterone acetate include: </strong><ul><li><strong>Reproductive system</strong> <strong>and sexual dysfunction </strong>— decreased libido, erectile dysfunction, reversible inhibition of spermatogenesis (very common).</li><li><strong>Hepatic toxicity </strong>— for example jaundice, hepatitis, and hepatic failure.</li><li><strong>Vascular </strong>— thromboembolic events, although a casual relationship has not been established (frequency unknown).</li><li><strong>Other common adverse effects include:</strong><ul><li>Dyspnoea.</li><li>Fatigue and lassitude.</li><li>Temporary depressive moods and restlessness.</li><li>Hot flushes and sweating.</li><li>Gynaecomastia (sometimes combined with tenderness to touch of the mamillae) — usually regresses after treatment withdrawal.</li></ul></li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/prostate-cancer/references/\">BNF 73, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/prostate-cancer/references/\">ABPI, 2017</a>]</p><!-- end field 0c7373e3-df9d-4657-b3ae-a46ddaf170a8 --><!-- end item 23885e3c-ca44-4bcb-b38b-247eda3052ca -->","subChapters":[]},{"id":"7e6a819f-37ba-57dd-865a-cffa8a6d4138","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field 8e8852d1-e4a1-4b19-9928-8c20a2ff7851 --><h3>Drug interactions </h3><!-- end field 8e8852d1-e4a1-4b19-9928-8c20a2ff7851 -->","summary":"","htmlStringContent":"<!-- begin item 4fb7507f-028b-4eba-a301-ea16eb831978 --><!-- begin field 9d8f4fa0-85a4-4fb3-aa73-3a732eef01e7 --><ul><li><strong>Possible drug interactions may occur with:</strong><ul><li>Antidiabetics (for example, pioglitazone and rosiglitazone) — blood levels of antidiabetics are increased, dosage adjustments may be required. </li><li>Statins (for example, simvastatin, atorvastatin) — the risk of statin-associated myopathy or rhabdomyolysis may be increased when given co-administered with cyproterone acetate, as both are metabolised by the CYP3A4 enzyme. </li><li>Antifungals (for example, ketoconazole, itraconazole, clotrimazole) and antiretrovirals (for example, ritonavir) — these are CYP3A4 enzyme inhibitors, so may reduce the metabolism of cyproterone acetate and increase the blood levels.</li><li>Antiepileptics (for example, phenytoin), antibiotics (for example, rifampicin) and St John's wort — these are CYP3A4 enzyme inducers, so may increase the metabolism of cyproterone acetate and reduce the blood levels.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/prostate-cancer/references/\">ABPI, 2017</a>]</p><!-- end field 9d8f4fa0-85a4-4fb3-aa73-3a732eef01e7 --><!-- end item 4fb7507f-028b-4eba-a301-ea16eb831978 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}